Last reviewed · How we verify
Dymelor (ACETOHEXAMIDE)
Dymelor (acetohexamide) is a small molecule drug developed by Lilly that targets the sulfonylurea receptor 1, Kir6.2. It is classified as an acetohexamide and was approved by the FDA in 1964 for the treatment of type 2 diabetes mellitus. Dymelor is now off-patent and has multiple generic manufacturers. As a sulfonylurea, it works by stimulating insulin release from the pancreas. It is no longer under patent protection, making it available as a generic medication.
At a glance
| Generic name | ACETOHEXAMIDE |
|---|---|
| Sponsor | Eli Lilly |
| Drug class | acetohexamide |
| Target | Sulfonylurea receptor 1, Kir6.2 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1964 |
Approved indications
- Diabetes mellitus type 2
Common side effects
Drug interactions
- atenolol
- betaxolol
- bisoprolol
- carteolol
- ciprofloxacin
- gatifloxacin
- labetalol
- levofloxacin
- metoprolol
- nadolol
- norfloxacin
- ofloxacin
Key clinical trials
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Incretin-based Drugs and Acute Pancreatitis
- Incretin-based Drugs and the Risk of Heart Failure
- Incretin-based Drugs and Pancreatic Cancer
- To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dymelor CI brief — competitive landscape report
- Dymelor updates RSS · CI watch RSS
- Eli Lilly portfolio CI